← All terms
CATEGORY: REGULATORY PATHWAYS
NHI (Japan National Health Insurance)
Japan's universal health insurance system covering over 70% of medical device spending. Obtaining NHI reimbursement listing after PMDA Shonin approval is critical for commercial viability in Japan.
Last reviewed 2026-08-05 · Reviewed by MedFlux Editorial Board · Editorial policy
WHEN IT APPLIES
NHI commonly refers to National Health Insurance systems (e.g., Taiwan NHI, Japan’s NHI reimbursement context) that determine payment and listing after (or parallel to) regulatory approval—critical for commercial access, not a substitute for device registration.
PROCESS / STEPS
- Separate regulatory approval from reimbursement/listing pathways.
- Prepare health-economic and clinical value dossiers for payers.
- Align coding, pricing applications, and post-listing evidence generation.
- Monitor policy changes that affect device categories and fees.
EXAMPLES
- In Japan, PMDA/MHLW approval and NHI reimbursement listing are sequential commercial gates for many devices.
RELATED GUIDES & TOOLS
SOURCES
Track regulatory signals related to NHI (Japan National Health Insurance) across 27 authorities in real time.
START FREE →